Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

ACQUISITION (Tables)

ACQUISITION (Tables)

9 Months Ended

Jun. 30, 2018

Schedule of consideration for Arcadian Services

The following table summarizes the allocation of the purchase consideration and the estimated fair value of the assets acquired and the liabilities assumed for the acquisition of Arcadian Services made by the Company:

Assets acquired:
Cash	$	25,900
Accounts receivable	57,100
Other assets	24,000
Intangibles	109,000
Goodwill	1,386,800
Total assets acquired	$	1,602,800

Liabilities assumed
Accounts payable	$	147,700
Accrued other liabilities	108,700
Notes payable	6,800
Total liabilities assumed	$	263,200

Net assets acquired	$	1,339,600

Consideration paid:
Initial investment in Arcadian Services	195,900
Long-term debt	555,000
Accrued interest	96,700
Payment on warrant outstanding	175,000
Forgiveness of loan in relation of acquisition	317,000
Total consideration	$	1,339,600

Schedule of unaudited Pro Forma Financial Information

The pro forma adjustments are based upon available information and certain assumptions that the Company believes are reasonable.

Pro Forma	For Three Months Ended June 30,						For Nine Months Ended June 30,
	2018			2017			2018			2017
Revenues	$	391,700		$	294,600		$	1,118,900		$	836,100
Net income (loss)	$	(2,937,200	)	$	1,687,300		$	(8,542,500	)	$	5,020,800
Basic and diluted loss per share:	$	(0.52	)	$	(0.67	)	$	(1.78	)	$	(2.15	)

Outstanding at Weighted average shares outstanding		5,698,523			2,535,394			4,793,273			2,336,283